<DOC>
	<DOCNO>NCT00030355</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness homoharringtonine treat patient refractory acute promyelocytic leukemia .</brief_summary>
	<brief_title>Homoharringtonine Treating Patients With Refractory Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety salvage therapy comprise homoharringtonine patient refractory acute promyelocytic leukemia . - Determine antileukemic efficacy drug patient . OUTLINE : Patients receive remission induction therapy comprise homoharringtonine ( HH ) IV continuously day 1-14 . Courses repeat every 4 week absence unacceptable toxicity complete remission ( CR ) achieve patient fails respond 3 course . Patients achieve CR induction therapy receive maintenance therapy comprise HH IV continuously day 1-7 . Maintenance treatment repeat every 4 week total 12 course absence disease progression unacceptable toxicity . Patients follow 4 week . PROJECTED ACCRUAL : A maximum 20 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute promyelocytic leukemia confirm morphologically ( 15 ; 17 ) translocation molecular polymerase chain reaction Refractory tretinoin , anthracyclines , arsenicbased therapy ( include arsenic trioxide ) alternative therapy high priority appropriate PATIENT CHARACTERISTICS : Age : 12 Performance status : Zubrod 03 Life expectancy : More 4 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL ALT great 3 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No active ischemia No uncontrolled cardiac condition ( e.g. , angina pectoris , cardiac arrhythmia , hypertension , congestive heart failure ) No myocardial infarction within past 12 week Other : No concurrent illness would preclude study No active malignancy No uncontrolled active infection No clinically significant screen serum chemistry result unless attributed acute promyelocytic leukemia No medical psychiatric condition would preclude informed consent study therapy HIV negative HTLVI HTLVII negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior concurrent leukapheresis allow Chemotherapy : See Disease Characteristics At least 15 day since prior systemic chemotherapy unless leukemia progression necessitates early therapy No concurrent systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Recovered prior therapy At least 15 day since prior antileukemic therapy unless leukemia progression necessitates early therapy No concurrent antileukemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>